Methylene Blue: Uses, History & Research Overview

Methylene blue (MB) is a synthetic compound known as methylthioninium chloride. Its chemical formula is C₁₆H₁₈ClN₃S. This dark blue dye and redox agent was first created in 1876 by chemist Heinrich Caro for textiles. Within a few years it was adopted in medicine: by 1880 R. Koch used MB as a biological stain [1]. Its striking blue colour and redox chemistry (ability to cycle between oxidised blue and reduced colourless “leucomethylene blue”) underlie its many applications. Methylene blue is on the World Health Organization’s List of Essential Medicines. It has established uses, particularly for treating methemoglobinemia.

Chemical Properties and Redox Mechanism

Methylene blue is a cationic phenothiazine dye that absorbs strongly around 668 nm. In solution it exists in equilibrium between the blue oxidised form (MB) and the reduced colourless form (leucomethylene blue). This redox property allows MB to accept and donate electrons in biological systems [3]. In the blood, MB readily enters red blood cells, where it is enzymatically reduced to leucomethylene blue. 

The reduced form then converts methaemoglobin (Fe³⁺) back to functional haemoglobin (Fe²⁺) [4]. This chemical re-reduction of heme iron restores oxygen-carrying capacity. Methylene blue also blocks nitric oxide synthases (NOS) and guanylate cyclase. This action lowers cyclic GMP levels and reverses harmful vasodilation [5]. In short, MB acts both as an electron (redox) mediator in cells and as a vasoconstrictor via NO/cGMP inhibition.

History and Key Discoveries

Methylene blue was the first fully synthetic drug used in medicine [6]. After its invention in 1876 for dyeing cotton, its medical potential was quickly realised. In 1891, Paul Ehrlich and colleagues found MB could treat malaria parasites (a rationalised “magic bullet” dye approach) [7]. MB later became a key compound in discovering many drugs. 

For instance, phenothiazine dyes helped create antimalarials like chloroquine and early antipsychotic drugs. In 1933, MB was discovered to act as an antidote for cyanide and carbon monoxide poisoning [9]. Throughout the 20th century MB remained in use as a surgical stain (Koch, 1880) and as a treatment for infections and blood disorders. Today its approved medical role is mainly in methemoglobinemia, but it has a long history in anaesthesia, emergency medicine, and infectious disease [1][6].

Mechanism of Action

Redox conversion: MB is reduced in cells to leucomethylene blue, which then chemically reduces methaemoglobin (Fe³⁺) to haemoglobin (Fe²⁺) [4]. This restores oxygen binding. (By comparison, vitamin C also can reduce Fe³⁺, but MB acts faster.)

Vasoconstriction

MB inhibits nitric oxide synthases (eNOS and iNOS) noncompetitively. It also blocks guanylate cyclase, which reduces cyclic GMP. The result is reversal of excessive NO–cGMP–mediated vasodilation [5]. In distributive shock (vasoplegia, septic shock), this mechanism can raise arterial pressure and reduce vasopressor needs [10][5].

Microbial action

MB has affinity for certain pathogens. It intercalates into cell membranes and may produce reactive oxygen species under light (photodynamic effect). In malaria, MB blocks the parasite's glutathione reductase. This stops heme polymerisation and works well with other antimalarials [7][11].

Clinical Uses

Methylene blue is mainly used for methemoglobinemia. However, it also has many other uses, both approved and off-label. Key uses include:

Methemoglobinemia

This is MB’s FDA-approved indication. In methaemoglobinemia, haemoglobin’s iron is oxidised to Fe³⁺ (methaemoglobin), impairing O₂ delivery. MB (typically 1–2 mg/kg IV) is given to rapidly reduce Fe³⁺ back to Fe²⁺ [4][12]. Patients often improve within minutes of treatment. MB corrects the blue-brown blood discolouration and hypoxia. The recommended dose is generally 1–2 mg/kg of a 1% solution intravenously over 5–30 minutes [4].

Vasoplegic Syndrome (Post-cardiac surgery shock)

Vasoplegia means very low blood pressure. It happens when blood vessels widen too much, often after heart surgery with cardiopulmonary bypass. MB (1.5–2 mg/kg IV) can restore vascular tone [13][14]. It inhibits the excess NO–cGMP signalling that drives vasodilation [5]. 

Clinically, MB infusion has improved blood pressure and reduced vasopressor requirements in vasoplegic patients [15][13]. Some protocols administer MB before or during high-risk cardiac surgery or as a rescue therapy if shock persists [13][14].

Septic Shock

By the same NO-blocking mechanism, MB has been studied in septic shock. Small trials show it can raise mean arterial pressure and systemic vascular resistance, transiently reversing refractory hypotension [10]. It is not standard of care but has been used when conventional vasopressors fail [10].

Hepatopulmonary Syndrome (HPS)

In advanced liver disease, abnormal pulmonary vasodilation causes hypoxaemia. MB (which lowers cGMP) can improve oxygenation in HPS [16]. Controlled studies showed that MB improved PaO₂ and A–a gradients in HPS patients. This likely happened due to constriction of lung capillaries.

Antimalarial Therapy

Methylene blue was one of the first synthetic antimalarial drugs (Ehrlich 1891) [7]. It was mostly abandoned due to malaria when chloroquine became common. But now, it's being looked at again in places with drug resistance. MB works against Plasmodium falciparum, especially its gametocytes. It also boosts chloroquine's effectiveness by blocking glutathione reductase. 

A 2018 meta-analysis showed that MB, often with artemisinin-based therapy, effectively kills P. falciparum in African patients. It also lowers the stages of parasite transmission. Effective antimalarial regimens have used total MB doses on the order of 36–72 mg/kg spread over 3 days [18]. These high doses are typically oral and divided (e.g., 200 mg bid for 3 days) and must be used cautiously due to nausea and GI upset [7][18].

Ifosfamide Neurotoxicity

Ifosfamide chemotherapy can produce a neurotoxic metabolite (chloroacetaldehyde), causing encephalopathy. MB is used to prevent or treat this. It acts as an alternative electron acceptor in mitochondria and inhibits formation of the toxic metabolite [19][20]. Clinically, IV MB (up to 50 mg every 6–8 hours, e.g., 1 mg/kg per dose) has resolved ifosfamide-induced confusion within hours in reported cases [20].

Diagnostic Dye in Surgery

MB’s vivid blue colour makes it useful as a surgical tracer. It is injected during operations to identify lymphatic or glandular structures. MB helps in sentinel lymph node mapping for breast and melanoma surgeries [21]. It’s also used for locating the parathyroid gland during thyroid or parathyroid surgery [22]. 

(MB stains hyperactive parathyroids blue, aiding their removal.) It can also mark intestinal lesions endoscopically and has been used as a cheap alternative to patent blue V for sentinel nodes [23]. In diagnostic microbiology, MB staining is a rapid test for Helicobacter pylori in gastric biopsies [24].

Photodynamic and Antimicrobial Therapy

Under light exposure, MB generates singlet oxygen and reactive radicals. This photodynamic effect is used on the skin. MB and red light treat MRSA infections and inactivate viruses like HIV and hepatitis C. MB has also been used intralesionally for conditions like psoriasis. Its broad-spectrum antimicrobial effect (especially with light) is an area of ongoing research [25].

Other Uses

Methylene blue can neutralise heparin in patients with protamine allergy, though high doses would be required [26]. Urologists use it for intracavernosal injection to treat high-flow priapism. This is because it inhibits nitric oxide–mediated vasodilation. In the past, it was used in small doses to treat methaemoglobin issues in malaria. It was also an early antiseptic for urinary tract infections. 

MB has been tested as a mood and stimulant drug by inhibiting MAO. It has also been researched for cognitive effects. However, these uses do not have regulatory approval.

Dosing and Administration

Methylene blue is usually given intravenously for systemic effects because oral bioavailability is variable. Typical dosing examples (adult) are:

Methemoglobinemia

1–2 mg/kg IV once (over ~5–30 min) [4]. This is repeated only if needed. (Doses >2 mg/kg can paradoxically cause more methaemoglobin if overdosed.)

Vasoplegia/Shock

1.5–2 mg/kg IV over 10–20 min is common for acute rescue [13][14]. Some protocols use a 1% MB solution infused slowly, with up to ~5 mg/kg total.

Ifosfamide encephalopathy

Often 50–100 mg IV repeated every 4–6 h (adult) until symptoms improve [20].

Malaria

Oral MB doses of ~100–300 mg every 12 h (totalling 36–72 mg/kg over 3 days) have been studied [18]. No standard regimen is approved.

MB infusions must be administered slowly to avoid acute haemodynamic effects. Because MB is a powerful dye, it can stain IV lines and tissues; hospitals typically use bright-coloured lines or warning labels for MB infusions.

Adverse Effects and Safety

At therapeutic doses (≤2 mg/kg), methylene blue is generally well tolerated. Most side effects are dose-related:

Discolouration

MB turns bodily fluids blue-green (e.g., urine, saliva) and can transiently discolour skin or sclera [28]. This is harmless and fades. Patients may notice blue urine or skin for a day or so after infusion.

Haemolysis

In patients with G6PD deficiency or severe anaemia, MB can precipitate haemolytic anaemia (due to oxidative stress) [29]. It is used with caution or contraindicated in known G6PD-deficient patients. High MB can induce Heinz-body haemolysis. Newborns have immature red cells, making them very sensitive. MB can lead to severe jaundice and methemoglobinemia in infants.

Serotonin Toxicity

MB is a reversible monoamine oxidase-A inhibitor. When taken with serotonergic drugs like SSRIs, SNRIs, or TCAs, it can cause serotonin syndrome. Symptoms include agitation, hyperthermia, and rigidity. This is of greatest concern at higher MB doses (>5 mg/kg total). Therefore, MB should not be given concurrently with most antidepressants.

Cardiovascular

Very high doses of MB can cause chest pain, cardiac arrhythmias, decreased cardiac output and increased pulmonary artery pressure [28]. For example, IV MB above ~5 mg/kg can induce hypertension or hypoxia.

Other

Allergic reactions (rash) are rare. MB may aggravate kidney or liver function in severe organ failure. It is contraindicated in patients with severe renal insufficiency because of slower clearance [32]. Since MB is teratogenic in animals, it is generally avoided in pregnancy unless absolutely needed.

In summary, dosing within recommended limits (<2 mg/kg) is usually safe, but high doses or at-risk patients (G6PD deficiency, neonates, concomitant drugs) require caution [33][34].

Research and Emerging Applications

Beyond its traditional uses, methylene blue is under active investigation in several areas:

Neurodegenerative and Cognitive Disorders

MB crosses the blood–brain barrier, and animal studies show it can enhance mitochondrial function and reduce oxidative damage. Early clinical trials have tested MB (also known as “methylthioninium chloride”) in Alzheimer’s and Parkinson’s diseases. MB inhibits tau and amyloid fibril formation, and some evidence suggests it can improve memory in healthy individuals [35][36]. 

For example, trials of MB analogues (“LMTX”) in mild Alzheimer’s showed mixed results. A recent review notes that MB has shown some cognitive benefit at specific doses, but larger trials are ongoing [36]. Its MAO-inhibiting and anti-inflammatory effects are also of interest in depression and bipolar disorder. However, evidence is preliminary, and MB is not an approved psychiatric drug.

Mitochondrial Medicine and Hormesis

Low-dose MB acts like an artificial electron carrier in mitochondria. This may boost ATP production and lower reactive oxygen species [37][36]. Experimental studies show that MB can delay cell ageing and boost memory in rodents. This happens when given in low doses (Atamna et al., 2008; Bruchey & Gonzalez-Lima, 2008). MB exhibits a “hormetic” effect: small doses enhance cell metabolism and brain function, whereas large doses are toxic [37]. Interest in MB is growing for age-related cognitive decline, stroke recovery, and energy metabolism disorders. However, human data is still limited.

Antiviral and COVID-19

During the COVID-19 pandemic, MB was proposed (and even trialled) as a broad-spectrum antiviral/anti-inflammatory agent [38]. Its ability to scavenge radicals and modulate immune responses made it a candidate for severe viral sepsis. A randomised trial began in 2020, but as of now there is no conclusive evidence MB benefits COVID-19 patients. More generally, MB’s antiviral action (via photodynamic viral inactivation or radical scavenging) is an experimental area.

Photodynamic Therapy (PDT)

As noted, MB absorbs light and produces singlet oxygen. In oncology, MB has been used as a photosensitiser to image and ablate tumours. Early studies show near-infrared MB fluorescence in head and neck cancer. There have also been reports on experimental PDT for melanoma. MB-based PDT also treats skin conditions and fungal infections, like onychomycosis, when used with light. This is a specialised research field.

Other Applications

MB is being explored in nanocarriers for targeted delivery and in diagnostics (e.g., as a fluorophore for imaging lymph nodes). Social media claims MB can help with “anti-ageing” or boost brain power. But experts say these uses are unproven and might be unsafe without a doctor’s guidance.

Final Words

In summary, methylene blue remains a versatile agent: a century-old dye turned medication. Its main life-saving role is treating methemoglobinemia; it also serves as a useful tool dye in surgery. Research continues on its novel actions (mitochondrial enhancer, neuroprotector, antimicrobial) [40][36]. However, outside of established indications, its use should be guided by evidence and monitored for safety.